Want to see PPBT full AI Analyst Report?
Purple Biotech (PPBT) Stock Statistics & Valuation Metrics
Total Valuation
Purple Biotech has a market cap or net worth of $10.32M. The enterprise value is -$4.20M.
- Market Cap
- $10.32M
- Enterprise Value
- -$4.20M
Share Statistics
Purple Biotech has 1,620,982 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,620,982
- Owned by Insiders
- ―
- Owned by Institutions
- 3.16%
Financial Efficiency
Purple Biotech’s return on equity (ROE) is -2.72 and return on invested capital (ROIC) is -272.87%.
- Return on Equity (ROE)
- -2.72
- Return on Assets (ROA)
- -1.50
- Return on Invested Capital (ROIC)
- -272.87%
- Return on Capital Employed (ROCE)
- -2.80
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.64M
- Employee Count
- 10
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Purple Biotech is -0.01. Purple Biotech’s PEG ratio is 0.00.
- PE Ratio
- -0.01
- PS Ratio
- 0.00
- PB Ratio
- 0.56
- Price to FCF
- -1.34
- Price to Operating Cash Flow
- -0.91
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Purple Biotech had revenue of 0 and earned -26.39M in profits. Earnings per share was -5.50.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -27.46M
- Pretax Income
- -26.49M
- Net Income
- -26.39M
- EBITDA
- -26.25M
- Earnings Per Share (EPS)
- -5.50
Cash Flow
In the last 12 months, operating cash flow was -7.76M and capital expenditures 0, giving a free cash flow of -7.76M billion.
- Operating Cash Flow
- -7.76M
- Free Cash Flow
- -7.76M
- Free Cash Flow per Share
- -0.71
Dividends & Yields
Purple Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -74.86%
- Earnings Yield
- -354.92%
Stock Price Statistics
- Beta
- 0.77
- 52-Week Price Change
- -84.33%
- 50-Day Moving Average
- 1.47
- 200-Day Moving Average
- 2.96
- Relative Strength Index (RSI)
- 45.30
- Average Volume (3m)
- 1.28M
Important Dates
Purple Biotech upcoming earnings date is Nov 13, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 07, 2026
- Next Earnings Date
- Nov 13, 2026
- Ex-Dividend Date
- ―
Financial Position
Purple Biotech as a current ratio of 1.27, with Debt / Equity ratio of 2.51%
- Current Ratio
- 1.27
- Quick Ratio
- 1.27
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.32
- Interest Coverage Ratio
- -704.05
Taxes
In the past 12 months, Purple Biotech has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Purple Biotech EV to EBITDA ratio is -0.88, with an EV/FCF ratio of -0.67.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.88
- EV to Free Cash Flow
- -0.67
- EV to Operating Cash Flow
- -0.68
Balance Sheet
Purple Biotech has $6.11M in cash and marketable securities with $134.00K in debt, giving a net cash position of $5.97M billion.
- Cash & Marketable Securities
- $6.11M
- Total Debt
- $134.00K
- Net Cash
- $5.97M
- Net Cash Per Share
- $3.68
- Tangible Book Value Per Share
- $0.45
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Purple Biotech is $17.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $17.00
- Price Target Upside
- 1282.11% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -151.47%
Scores
- Smart Score
- ―
- AI Score
- 42
